Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Maximally Tolerated RAAS Blockade and Spironolactone Therapy on Urinary Proteinuria and Progression of Type II Diabetic Nephropathy in African Americans and Other Patient Cohorts.

NCT03502031 is registered in ClinicalTrials.gov with James A. Tumlin, MD as lead sponsor.

NCT NCT03502031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03502031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Maximally Tolerated RAAS Blockade and Spironolactone Therapy on Urinary Proteinuria and Progression of Type II Diabetic Nephropathy in African Americans and Other Patient Cohorts.
Lead sponsor
James A. Tumlin, MD
Phase
Phase 4
Overall status
Unknown status
Start date
October 1, 2018
Completion date
October 1, 2024
Enrollment
72 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic nephropathy type 2, renal insufficiency, chronic